Biocon Ranked 7th on Top Global Pharma & Biotech Employers list 2018

Deepthi | Myequity news | Date : 30-10-2018 14:55:00 IST

Biocon Ltd, Asia's premier biopharmaceuticals company, has moved up in the Top 10 Global Biotech Employers ranking for 2018 and continues to be the only Company from Asia to feature on the prestigious U.S.-based Science magazine's annual 'ScienceCareers Top 20 Employers' list, since its debut in 2012. Ranked at No.1 amongst global pharma and biotech companies in 2018, Biocon's position has moved up two ranks from No.9 last year.

The ranking is a result of a global survey conducted by the Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally.

Kiran Mazumdar Shaw, CMD, Biocon said: "We are delighted to be ranked at No. 7 on Science magazine's Top Global Pharma & Biotech Employers List for 2018. This is a recognition of Biocon's high-end scientific talent who are aligned with the vision of a socially responsible organization that is making a difference to global healthcare through innovation and affordable access for patients. It encourages us to continue our journey of endurance with a focus on nurturing a culture of quality and compliance aimed at operational excellence. It is also recognition of the grit, courage and commitment needed to emerge among the frontrunners in the global biosimilars race while operating in India's risk-averse investment environment."


The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics. This year more than 8,000 people participated, the most in the history of the survey; and these respondents were from North America {63%), Europe {24%), and Asia/Pacific Rim {9%); 93% of these were from biotechnology, biopharmaceutical, and pharmaceutical companies.

About Biocon:

Biocon Limited is a fully-integrated, innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and taken differentiated Small Molecules, Novel Biologics and a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh-Insulin and Insulin Glargine) from 'Labto Market' in India, key emerging and developed markets. It has a large portfolio of biosimilars under clinical development with three of these approved in developed markets of US, EU, Japan and Australia.


More from Myequity